ライフサイエンスコーパス: virus strain

1 t bind efficiently to the boosting influenza virus strain.

2 rain, and a recently emerging H7N9 influenza virus strain.

3 ls more slowly than their parental wild-type virus strain.

4 edical conditions increased severity despite virus strain.

5 nes into the genome of an oncolytic vaccinia virus strain.

6 prevent human infection with any influenza A virus strain.

7 of a highly pathogenic avian H7N1 influenza virus strain.

8 elong humoral immunity against the homotypic virus strain.

9 MHC class II expression by RDC and with the virus strain.

10 to generate W7-791, a live attenuated mutant virus strain.

11 ponse modules under infections from multiple virus strains.

12 ss-reactivity with past and future influenza virus strains.

13 that prevent infection by diverse influenza virus strains.

14 tive immunity against heterologous influenza virus strains.

15 uish influenza virus fusion properties among virus strains.

16 t heterovariant and heterosubtypic influenza virus strains.

17 decay of RNA in cells infected with multiple virus strains.

18 ly mutated variant (var) thereof as parental virus strains.

19 n, including sieving effects on breakthrough virus strains.

20 e than the HAs from other seasonal influenza virus strains.

21 immunity that are protective against diverse virus strains.

22 igs but also in mice immunized with the same virus strains.

23 th a vaccine containing a mixture of diverse virus strains.

24 (LOD) analyses were performed with five FluA virus strains.

25 to evade host immunity acquired to previous virus strains.

26 assessing the risks associated with emergent virus strains.

27 e limited by the emergence of drug-resistant virus strains.

28 e of pathogenicity across multiple influenza virus strains.

29 ruses and current human seasonal influenza A virus strains.

30 cross-protection against different influenza virus strains.

31 revent infection against genetically diverse virus strains.

32 n neutralize seasonal and pandemic influenza virus strains.

33 effective but highly specific for particular virus strains.

34 sfully utilized for the detection of various virus strains.

35 or identifying antigenically novel influenza virus strains.

36 d toward new antigenically drifted influenza virus strains.

37 seasonal or pandemic circulating influenza A virus strains.

38 for distinguishing virus of various sizes or virus strains.

39 outside of Africa and to seasonal influenza virus strains.

40 ion compared to prototypic macrophage-tropic virus strains.

41 red to prototypic "highly macrophage-tropic" virus strains.

42 selected group of genetically diverse mumps virus strains.

43 ), and potentially pandemic (H5N1) influenza virus strains.

44 ction or vaccination with seasonal influenza virus strains.

45 f sequence diversity among natural influenza virus strains.

46 ng frame of the PB1 gene of most influenza A virus strains.

47 pearance of existing seasonal H1N1 influenza virus strains.

48 of such vaccines against emerging influenza virus strains.

49 erminants in seasonal and pandemic influenza virus strains.

50 nhibited wild-type and Enfuvirtide-resistant virus strains.

51 protect against a wide spectrum of influenza virus strains.

52 he hemagglutinin protein of circulating H3N2 virus strains.

53 ection and subtyping of avian influenza (AI) virus strains.

54 that are conserved among different influenza virus strains.

55 gglutinin (HA) can neutralize many influenza virus strains.

56 vaccines and may provide protection to novel virus strains.

57 as cross-subtype protection against various virus strains.

58 tently found mutated in rodent-adapted Ebola virus strains.

59 stic recall of antibody to earlier influenza virus strains.

60 ly and accurate characterization of emerging virus strains.

61 n with its host and genetic exchange between virus strains.

62 ently against homologous and closely matched virus strains.

63 t elicits broad protection against different virus strains.

64 cine virus strains or with differing vaccine virus strains.

65 cosal, and cellular immunity against diverse virus strains.

66 nfection with a series of distinct influenza virus strains.

67 design of novel inhibitors against resistant virus strains.

68 PB2 of human from that of avian influenza A virus strains.

69 on into the genetic basis of mouse hepatitis virus strain 1 (MHV-1) pneumovirulence.

70 fat diet-caused obesity and murine hepatitis virus strain-3 (MHV-3)-induced fulminant hepatitis due t

71 in a sample of a virulent strain of dengue-2 virus (strain 44/2), which was recovered from a patient

72 ace-immobilized HA and NA of the influenza A virus strain A/California/04/2009 and a novel, to our kn

73 ia/20/1999 and 2009 pandemic swine influenza virus strain A/California/04/2009.

74 14D is applicable in both seasonal influenza virus strain A/New Caledonia/20/1999 and 2009 pandemic s

75 rus engineering (SAVE) approach to influenza virus strain A/PR/8/34 to rationally design live attenua

76 tranasal infection with a pandemic influenza virus strain (A/California/4/09 [CA09]), a human seasona

77 sublethal dose of a less virulent influenza virus strain (A/WSN/33 [H1N1]) resulted in a milder card

78 E) cultures, and functional studies with two virus strains (a pandemic GII.4 and a bile acid-dependen

79 Using 6 influenza A virus strains (A/Puerto Rico/8/1934, A/Aichi/2/1968 x A/

80 (1%-1.5%) of 2009 pandemic influenza A/H1N1 virus strains (A[H1N1]pdm09) are oseltamivir resistant,

81 viruses, including a pandemic H1N1 influenza virus strain, a highly pathogenic H5N1 avian influenza v

82 Like all influenza A virus strains, A(H5N1) viruses evolve rapidly.

83 n response to infection with two influenza A virus strains, A/Udorn/72 and A/WSN/33.

84 ences or the NCR sequences of two other H1N1 virus strains, A/WSN/1933 and A/New York/312/2001, were

85 al compounds against the following influenza virus strains: A/WSN/33 (H1N1), A/Udorn/72 (H3N2), and B

86 Previous work showed that mouse hepatitis virus strain A59 (MHV-A59) with a mutated catalytic site

87 Mouse hepatitis virus strain A59 infection of mice is a useful tool for

88 nfection with the gliatropic mouse hepatitis virus strain A59.

89 The two virus strains achieved similar peak titers in IRF-3(+/+)

90 ntaining neutralizing epitopes from multiple virus strains across subgroups to reduce immune patholog

91 Influenza A virus strains adapt to achieve successful entry into hos

92 rtment of IAV gene segments from coinfecting virus strains adapted to different hosts in conjunction

93 to understand how past exposure to influenza virus strains affects the response to subsequent immuniz

94 ow that DRELFA can discriminate a particular virus strain against others of the same subtype or commo

95 genomics between a virulent and an avirulent virus strain and construct chimeras to map their locatio

96 Depending on virus strain and host immune status, acute infections by

97 tability of influenza viruses depends on the virus strain and host species and that HA stability can

98 ion and virulence are strongly influenced by virus strain and host species.

99 how acid-induced membrane fusion varies with virus strain and influences tropism.

100 aphical pattern in the distribution of Lassa virus strains and a westward movement of the virus acros

101 agent was tested on 21 prototype influenza A virus strains and confirmed to be specific for its inten

102 derstanding antigenic variation in influenza virus strains and how the human immune system recognizes

103 tigenic similarity in foot-and-mouth disease virus strains and in influenza strains, where the struct

104 14 seasonal H1N1 or H3N2 prototype influenza virus strains and is also not reactive with seven other

105 f this system allows efficient generation of virus strains and presents an alternative approach for i

106 A) could confer immunity to the diverse H5N1 virus strains and provide information for effective vacc

107 s that neutralize a broad range of influenza virus strains and subtypes by binding to this domain has

108 ), which are conserved among all influenza A virus strains and subtypes, could be manufactured in adv

109 oteins conserved among all known influenza A virus strains and subtypes, so it could be used early in

110 adly neutralize a wide spectrum of influenza virus strains and subtypes.

111 neutralization to highly divergent influenza virus strains and subtypes.

112 Instead, interactions between individual virus strains and the cellular microenvironment of the i

113 Interactions between virus strains and the microenvironment of individual ATM

114 ties of previously uncharacterized West Nile virus strains and West Nile-like viruses.

115 IV antibody D5 10-100-fold (depending on the virus strain), and (iv) increases synergy between 2F5 an

116 in, a highly pathogenic H5N1 avian influenza virus strain, and a recently emerging H7N9 influenza vir

117 thoviruses have been conducted with a single virus strain, and the effect of intragenus competition b

118 on, 5 of 12 (42%) urine samples had multiple virus strains, and 50% of vaccine recipients were infect

119 ssays using resynthesized compounds, several virus strains, and detailed virology assays resulted in

120 Mixed infections with seasonal influenza A virus strains are a common occurrence and an important s

121 respiratory influenza, and highly pathogenic virus strains are characterized by massive infiltration

122 Vaccines that match circulating virus strains are needed for optimal protection.

123 Influenza virus strains are often pleiomorphic, a characteristic t

124 New vaccine virus strains are selected, replacing older strains to b

125 eact with strains emerging after the vaccine virus strains are selected.

126 ary IgA to influenza A(H3N2) and influenza B virus strains as early as 14 days after vaccination but

127 vidence and support the suitability of these virus strains as the next-generation BTV vaccines.

128 upport and validate the suitability of these virus strains as the next-generation vaccines for BTV.

129 rgeted an essential gene to develop disabled virus strains as vaccine candidates.

130 show that the V330 variant is lethal on both virus strain backgrounds, whereas the L330 variant is at

131 uenza A virus binds TRIM25, although not all virus strains block the interferon response, suggesting

132 Differences in how virus strains "breathe" may affect epitope exposure and

133 suggests that JPV-BH and JPV-LW are the same virus strain but were obtained at different passages fro

134 This region varies not only among Zika virus strains but also in other flaviviruses, which sugg

135 Differential behavior of virus strains can be exploited to elucidate gene functio

136 za are limited, and drug-resistant influenza virus strains can emerge through minor genetic changes.

137 lts highlight that even very closely related virus strains can produce significantly different pathog

138 tive mutations 627K or 701N, pH1N1 influenza virus strains can replicate efficiently in the low tempe

139 tive interfering (DI) RNA produced by Sendai virus strain Cantell.

140 ts could be used as sentinels for monitoring virus strains circulating in specific segments of the po

141 dies against A/H1N1, A/H3N2, and B influenza virus strains collected pre- and postvaccination using h

142 ics can result when animal-derived influenza virus strains combine with seasonal strains.

143 Virus strains competent to enter ECs replicate with diff

144 ength NS1A proteins from different influenza virus strains, controversy remains over the actual biolo

145 logical antibody levels to a given influenza virus strain correlate with low production of antibody-s

146 ine that protects against multiple influenza virus strains could alleviate the continuing impact of t

147 example of how genetic reassortment between virus strains could produce phenotypes that are distinct

148 ighly pathogenic avian (HPAI) H5N1 influenza virus strains could productively replicate in murine mac

149 e was a worldwide replacement of the initial virus strain (CPV type 2) by a variant (CPV type 2a) cha

150 the genotypic characteristics of circulating virus strains, critical information for the programs.

151 ctious clone of the highly pathogenic rabies virus strain CVS-N2c and replaced its cognate glycoprote

152 s in mice infected with encephalomyocarditis virus strain D (EMCV-D), which has tropism for the insul

153 Finally, we identified virus strain-dependent variability in type I interferon

154 were infected with a patient-derived dengue virus strain developed clinical symptoms of the disease

155 o detect, type and subtype influenza A and B virus strains directly from clinical samples in a single

156 Influenza virus strains diverge by 1 to 2% per year, and commercia

157 ully diagnosing and distinguishing different virus strains (DMV, PWMV and novel CeMVs) using FFPE sam

158 d to rapidly and reliably survey circulating virus strains down to the molecular level is ever presen

159 of latent infections or reinfection with new virus strains during pregnancy can result in fetal infec

160 Both virus strains elicited minimal pathology and a lack of s

161 and where and how novel pathogenic influenza virus strains emerge.

162 ere found to be conserved among the analyzed virus strains, except for replacement of lysine with arg

163 Phenotypically, the new T/F virus strains exhibited a range of neutralization sensit

164 We generated a mutant influenza virus strain expressing NS1-W187R to destabilize this se

165 didymal white fat in mice using pseudorabies virus strains expressing different reporters together wi

166 vivo, I constructed a novel murine leukemia virus strain (FMLV-IL-1beta) that encodes the mature for

167 nt (disabled infectious single-cycle [DISC]) virus strains for a number of serotypes and reported pre

168 ise vaccine match with currently circulating virus strains for efficacy, requiring constant surveilla

169 ld be taken into consideration when choosing virus strains for future molecular studies.

170 , health authorities recommend three or four virus strains for inclusion in the annual influenza vacc

171 We sequenced and isolated 77 Lassa virus strains from 16 Nigerian states.

172 uences formed a new cluster related to Lassa virus strains from Hylomyscus pamfi Within lineages II a

173 ts that FCs are a sink for, not a source of, virus strains from the GP.

174 Variant influenza virus strains generated through antigenic shift or drift

175 exposure to either of two seasonal influenza virus strains, H1N1 and H3N2.

176 he Middle East and South Asia, an older H9N2 virus strain has been replaced by a new reassortant stra

177 rapid emergence of drug-resistant influenza virus strains has reduced its efficacy.

178 en sequence variations in seasonal influenza virus strains have affected regions responsible for prot

179 lderly, and immunocompromised patients; some virus strains have also been associated with neurologica

180 g their potential to reassort with wild-type virus strains have been voiced.

181 Different influenza virus strains have caused a number of recent outbreaks k

182 onomers and neutralized heterologous primary virus strains HIV-2(7312A) and HIV-2(ST).

183 Abs neutralized a third heterologous primary virus strain, HIV-2(UC1).

184 to be sufficiently highly conserved between virus strains (ie, the 5'-untranslated region and cis-ac

185 values of >20 to 200 for different influenza virus strains; (iii) inhibit a wide spectrum of influenz

186 investigated the N9 NA from a zoonotic H7N9 virus strain in order to determine its possible role in

187 (H1N1pdm) virus is the predominant influenza virus strain in the human population.

188 g confirmed the reappearance of pretreatment virus strains in all cases.

189 tbreak suggests there are at least two Ebola virus strains in DR Congo, which have independently cros

190 tween strains in pigs and seasonal influenza virus strains in humans is also important in assessing t

191 cation inhibitor of a variety of influenza A virus strains in Madin-Darby canine kidney (MDCK) cells,

192 ely against lethal avian and swine influenza virus strains in mice, and induced robust immunity again

193 to 3 copies/ml, (ii) about one-third of the virus strains in reservoirs are replication incompetent,

194 both homologous and heterologous influenza B virus strains in the mouse model.

195 defect is significantly exacerbated in both virus strains in the presence of cyclosporine (CsA), ind

196 Influenza B virus strains in trivalent influenza vaccines are freque

197 nd H5 subtypes) and 2 (H3 subtype) influenza virus strains in vitro.

198 o provide broad protection against divergent virus strains in vivo.

199 is study, we show across a range of vaccinia virus strains, including the current clonal smallpox vac

200 ction or vaccination with seasonal influenza virus strains influences the ability to mount a protecti

201 In this work, we report that the initial virus strains introduced in Mexico came from Europe and

202 are related to genotypic differences in the virus strains involved.

203 ity maturation to HA1 of all three influenza virus strains irrespective of the vaccine platform.

204 Typing of influenza virus strains is an important aspect of global health su

205 re, the B cell response to variant influenza virus strains is not dictated by the composition of the

206 rent epidemiologically important influenza A virus strains is not known.

207 analyses showed highest identities with Zika virus strains isolated from Brazil during 2015.

208 Although virus strains isolated from herpetic lesions cause limit

209 ietic CD34+ stem cells with low-passage CCHF virus strains isolated from human patients.

210 and analyzed 441 wild-bird origin influenza virus strains isolated from wild birds inhabiting North

211 ost vaccination with simian immunodeficiency virus strain mac239 (SIVmac239) Gag-Pol and Env provided

212 viruses, raising concern that certain mumps virus strains may escape vaccine-induced immunity.

213 is isolates has suggested that more than one virus strain might concurrently infect the same parasite

214 cal studies, melanin overproducing oncolytic virus strains might be used in clinical trials in patien

215 upon the accurate prediction of circulating virus strains months in advance of the actual influenza

216 Rift Valley fever virus strain MP-12 was generated by serial plaque passag

217 s were then boosted with either the vaccinia virus strain NYVAC or a variant with improved replicatio

218 tent, attenuated recombinant of the vaccinia virus strain NYVAC.

219 ogma by constructing a recombinant influenza virus strain of A/PR8/34 (H1N1) in which expression of N

220 and sheds light on an additional neurotropic virus strain of the archetype variety.

221 dies that can bind but do not inhibit dengue virus strains of other serotypes.

222 infection is restricted to type A influenza virus strains of the H2N2 subtype.

223 pact of intrauterine infection with multiple virus strains on the pathogenesis and long-term outcome

224 that are not found in circulating influenza virus strains or have not been previously identified to

225 years in a row with either identical vaccine virus strains or with differing vaccine virus strains.

226 This effect is independent of cell line, virus strain, or batch of pooled human serum used.

227 m of interest regardless of cell type, HIV-1 virus strain, or experimental perturbation.

228 59,984-bp-long genome sequence of P. globosa virus strain PgV-16T, encoding 434 proteins and eight tR

229 eterologous mouse-adapted A/PR/8/1934 (H1N1) virus strain (PR8).

230 and Sudan Ebolavirus and 4 different Marburg virus strains produced severe, but more slowly progressi

231 ged between 0.05 and 1.21%, depending on the virus strain, producer cell type and gp120 V1-V3 loop si

232 RNA (satRNA) associated with Cucumber mosaic virus strain Q (Q-satRNA) has a propensity to localize i

233 d), a satRNA associated with Cucumber Mosaic Virus strain Q (Q-satRNA) has the propensity to localize

234 The virulence of Soromba-R, a Lassa virus strain recently isolated from southern Mali, was a

235 So far, circulating virus strains remain similar under continuous monitoring

236 ne of the few experimental vaccine candidate virus strains reported to be able to induce protection a

237 enza A(H5N1) virus and other avian influenza virus strains represent major pandemic threats.

238 Our data show that multiple different virus strains seeded and were maintained throughout the

239 76, which is conserved in >99% of influenza virus strains sequenced to date, was identified as being

240 upon inoculation with human H1N1 influenza A virus strains, several swine influenza viruses, and infl

241 gglutinins (HAs) from previously circulating virus strains; several of these antibodies, which were p

242 IAV HAs from different virus strains showed consistently reduced binding to bot

243 analysis of the low- and high-pathogenicity virus strains showed marked variability.

244 Comparison of closely related virus strains shows that CRISPR targeting drives virus g

245 intervals to combat newly arising influenza virus strains, so that a universal vaccine is highly des

246 acid difference between viruses can dictate virus strain-specific differences in suppression of the

247 immunocompromised mouse strains, we observed virus strain-specific differences in the duration of inf

248 dies indicate that host species-specific and virus strain-specific interactions of viral molecules wi

249 Influenza virus strain-specific monoclonal antibodies (mAbs) provi

250 in an acute infection with a closely related virus strain, suggesting that persistent TLR stimulation

251 A shift in circulating JE virus strains suggests that a genotype shift phenomenon

252 ion of a vaccine matched to a newly emerging virus strain takes months.

253 , which is comprised of an attenuated DENV-2 virus strain (TDV-2) and three chimeric viruses containi

254 ody titer of the sera was lower against some virus strains than others, all viruses were readily neut

255 The A(H7N9) virus strain that emerged in 2013 was associated with a

256 emains a challenge to identify an attenuated virus strain that has an optimal balance between attenua

257 A Sindbis virus strain that in wild-type (WT) mice only causes dis

258 c response to VACV, especially against those virus strains that are most dependent on cross-presentat

259 by generating an immune response toward the virus strains that are predicted to circulate in the upc

260 ve used a collection of vesicular stomatitis virus strains that had been evolving either under positi

261 el810), which is representative of influenza virus strains that have caused severe morbidity and mort

262 ernal genes of all current LAIVs derive from virus strains that were isolated between 1957 and 1960 a

263 L20 in the context of a highly neurovirulent virus strain, the HSV-1(McKrae) genome was cloned into a

264 For the recombinant A/WSN/33 (rWSN) virus strain, the inability to stimulate PI3K had minima

265 Using whole-virus strains, the analytical sensitivity for representa

266 seasonal as well as novel pandemic influenza virus strains therefore obviating the need for annual va

267 rotection limited to the infection with same virus strains; therefore, the composition of influenza v

268 ded their distinction from circulating human virus strains through linking receptor specificity to hu

269 and determine the lineage of human influenza virus strains through the detection of one or more signa

270 s vaccines protect mostly against homologous virus strains; thus, regular immunization with updated v

271 chain antibodies by using oncolytic vaccinia virus strains to enhance their therapeutic efficacy.

272 that recognize a broader number of influenza virus strains to prevent infection and transmission.

273 this may be the ability of certain influenza virus strains to productively replicate in macrophages.

274 logical processes, from the emergence of new virus strains to the effectiveness of vaccination progra

275 We developed two LDTs for FluA virus strain typing on the Panther Fusion instrument, en

276 ated NS1 proteins encoded by two influenza A virus strains, Udorn/72/H3N2 (Ud) and Puerto Rico/8/34/H

277 The A(H1N1)pdm09 virus strain used in the live attenuated influenza vacci

278 family glycoproteins not encoded by vaccinia virus strains used as vaccines.

279 recombinant A/Puerto Rico/8/34 (rPR8) mutant virus strain was attenuated and caused reduced morbidity

280 The virus strain was genotype D9, which was circulating in t

281 For a panel of avian influenza A virus strains, we find evidence for a trade-off between

282 Three influenza A virus strains were also compared.

283 The circulating and vaccine H3N2 virus strains were different clades, with the vaccine st

284 While the two virus strains were found to be cocirculating in a mixed-

285 The virus strains were genotyped, and their time origin was

286 A total of 189 virus strains were identified.

287 Four T/F virus strains were inoculated into rhesus macaques, and

288 ice against infection with the H1N1 and H3N2 virus strains when administered before or after challeng

289 directed against a neutralization-sensitive virus strain, whereas neutralizing activities emerging a

290 l cells limit replication of human influenza virus strains, whereas avian influenza viruses overcome

291 is with the A/PR/8/34 (H1N1) (PR8) influenza virus strain, which is lethal in KO mice even at low dos

292 The virus strain, which was previously provided by the Onder

293 A neurovirulent Sindbis virus strain with neuroinvasive properties (SVNI) causes

294 Virus strains with a history of repeated genetic bottlen

295 nfectivity and cellular tropism of influenza virus strains with different receptor specificities.

296 reverse genetics system to rescue defective virus strains with large deletions in an essential BTV g

297 has been a widespread emergence of influenza virus strains with reduced susceptibility to neuraminida

298 ne segments from the 2009 pandemic influenza virus strain without prior adaptation.

299 C57BL/6 mice with 1 x 10(7) PFU of vaccinia virus strain WR results in blepharitis, corneal neovascu

300 3 x 10(6) PFUs of virulent Rift Valley fever virus strain ZH-501 (RVFV ZH-501) at 126 days after vacc